Clinical Trial Update: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

View source ↗

Summary

A completed Travera Inc trial evaluating TraveraRTGx and a tumor-cell biomarker intended to guide rapid therapy decisions across multiple cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Malignant Ascites
• Malignant Melanoma
• Malignant Pleural Effusion
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma
• Renal Cell Carcinoma

Drugs mentioned

• TraveraRTGx

Snippet

Sponsor: Travera Inc | Conditions: Pleural Effusion, Malignant, Ascites, Malignant | Status: COMPLETED